HIV protease inhibitors in pregnancy : pharmacology and clinical use. (Q38081072)

28 August 2017

HIV protease inhibitors in pregnancy : pharmacology and clinical use. (English)

1 reference

28 August 2017

1 reference

2

Mona R Loutfy

1 reference

28 August 2017

Nisha Andany

1

1 reference

28 August 2017

1 March 2013

1 reference

28 August 2017

1 reference

28 August 2017

73

1 reference

28 August 2017

3

1 reference

28 August 2017

229-247

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-013-0017-3

28 August 2017

0 references

cites work

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Estimating the impact of antiretroviral therapy: regional and global estimates of life-years gained among adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

The impact of antiretroviral treatment on mortality trends of HIV-positive adults in rural Uganda: a longitudinal population-based study, 1999-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Fertility desires and intentions of HIV-positive women of reproductive age in Ontario, Canada: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Trends in management and outcome of pregnancies in HIV-infected women in the UK and Ireland, 1990-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

"Life is still going on": reproductive intentions among HIV-positive women and men in South Africa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

The changing face of HIV in pregnancy in Rhode Island 2004-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Canadian HIV pregnancy planning guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Antiretroviral regimens in pregnancy and breast-feeding in Botswana

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

High prevalence of unintended pregnancies in HIV-positive women of reproductive age in Ontario, Canada: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

High incidence of unplanned pregnancy after antiretroviral therapy initiation: findings from a prospective cohort study in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Use of Specific Antiretroviral Regimens Among HIV-Infected Women in Italy at Time of Conception: 2001–2011

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

In utero and postnatal exposure to antiretrovirals among HIV-exposed but uninfected children in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Antiretroviral treatment in pregnancy: a six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Hepatotoxicity associated with nevirapine use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

CD4+ count-guided interruption of antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Pregnancy and progression to AIDS: results of the French prospective cohorts. SEROGEST and SEROCO Study Groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Antiretroviral medications during pregnancy for therapy or prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Antiretroviral therapy in HIV-infected pregnant women and their infants: current interventions and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Reduced lopinavir exposure during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Pharmacokinetics of antiretrovirals in pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Clinical pharmacology of HIV protease inhibitors in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Pharmacokinetic changes during pregnancy and their clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Nelfinavir plasma concentrations are low during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Transplacental passage of protease inhibitors at delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Concentrations of protease inhibitors in cord blood after in utero exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Atazanavir pharmacokinetics with and without tenofovir during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Transplacental passage of ritonavir-boosted darunavir in two pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Management of human immunodeficiency virus infection in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Risk of birth defects associated with nelfinavir exposure during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Antiretroviral therapy during pregnancy and the risk of an adverse outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Combination antiretroviral therapy and duration of pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

21 January 2018

12 December 2020

Antiretroviral therapy during pregnancy and premature birth: analysis of Swiss data

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Lack of an effect of protease inhibitor use on glucose tolerance during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Lack of effect on prematurity, birth weight, and infant growth from exposure to protease inhibitors in utero and after birth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Antiretroviral therapy and preterm delivery-a pooled analysis of data from the United States and Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric Spectrum of HIV Disease, 1989-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Combination antiretroviral use and preterm birth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

No relation between in-utero exposure to HAART and intrauterine growth retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Protease inhibitor-associated increased risk of preterm delivery is an immunological complication of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Association of Prenatal and Postnatal Exposure to Lopinavir-Ritonavir and Adrenal Dysfunction Among Uninfected Infants of HIV-Infected Mothers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Epidemiology and causes of preterm birth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Protease inhibitors and decreased birth weight in HIV-infected pregnant women with impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Lopinavir tablet pharmacokinetics with an increased dose during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Lopinavir exposure with an increased dose during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Lopinavir/ritonavir in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Use of darunavir and enfuvirtide in a pregnant woman

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Efficacy of darunavir despite low plasma trough levels during late pregnancy in an HIV-hepatitis C virus-infected patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Saquinavir, the pioneer antiretroviral protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Safety and efficacy of saquinavir soft-gelatin capsules + zidovudine + optional lamivudine in pregnancy and prevention of vertical HIV transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Once-daily saquinavir-hgc plus low-dose ritonavir (1200/100 mg) in HIV-infected pregnant women: pharmacokinetics and efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Chronic use of indinavir in albino rat pregnancy (Rattus norvegicus albinus, Rodentia, Mammalia): Biological assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

A review of nelfinavir for the treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Nelfinavir and nevirapine side effects during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Safety and efficacy of fosamprenavir in human immunodeficiency virus-infected pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Pharmacokinetic profile in late pregnancy and cord blood concentration of tipranavir and enfuvirtide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Prevention of mother-to-child transmission of multi-drug resistant HIV-1 using maternal therapy with both enfuvirtide and tipranavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

British HIV Association guidelines for the management of HIV infection in pregnant women 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Antiretroviral Therapy and Congenital Abnormalities in Infants Born to HIV-1-Infected Women in the United Kingdom and Ireland, 1990 to 2003

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0017-3

Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum.

21 January 2018

1 reference

12 December 2020

Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia

1 reference

12 December 2020

Transplacental passage of nevirapine, nelfinavir and lopinavir

1 reference

12 December 2020

Fertility desires and intentions of HIV-positive men and women

1 reference

12 December 2020

Protease inhibitor use in 233 pregnancies

1 reference

12 December 2020

The effects on infants of potent antiretroviral therapy during pregnancy: a report from Spain

1 reference

12 December 2020

Effect of protease inhibitor therapy on glucose intolerance in pregnancy

1 reference

12 December 2020

Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost?

1 reference

12 December 2020

Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial

1 reference

12 December 2020

U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States

1 reference

12 December 2020

Fertility intentions of women of reproductive age living with HIV in British Columbia, Canada

1 reference

12 December 2020

Antiretroviral agents during pregnancy: consequences on hematologic parameters in HIV-exposed, uninfected newborn infant

1 reference

12 December 2020

Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study

1 reference

12 December 2020

Neonatal screening for congenital adrenal hyperplasia: a pilot study in France

1 reference

12 December 2020

Combination antiretroviral therapy with protease inhibitors in HIV-infected pregnancy

1 reference

12 December 2020

Changing trends in pregnancy outcome among HIV-infected women between 1985 and 1997 in two southern French university hospitals

1 reference

12 December 2020

Increased rates of preterm delivery are associated with the initiation of highly active antiretrovial therapy during pregnancy: a single-center cohort study

1 reference

12 December 2020

Multicenter review of protease inhibitors in 89 pregnancies

1 reference

12 December 2020

Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084.

1 reference

12 December 2020

Canadian consensus guidelines for the care of HIV-positive pregnant women: putting recommendations into practice.

1 reference

12 December 2020

The AmRo study: pregnancy outcome in HIV-1-infected women under effective highly active antiretroviral therapy and a policy of vaginal delivery

1 reference

12 December 2020

Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine

1 reference

12 December 2020

Comparison of lopinavir level between the two formulations (soft-gel capsule and tablet) in HIV-infected pregnant women

1 reference

12 December 2020

10.1007/S40265-013-0017-3

Identifiers

DOI

1 reference

PubMed ID

23404092

Dimensions Publication ID

28 August 2017

0 references

1 reference

PubMed ID

23404092